Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
03681 SINOMAB BIO-B
RTNominal unchange1.230 0.000 (0.000%)
Others

25/06/2021 15:16

SinoMab Bio (03681) gets IND application approval

[ET Net News Agency, 25 June 2021] SinoMab BioScience Limited (03681) said the China
National Medical Products Administration of China (NMPA) has approved the Investigational
New Drug (IND) application of SN1011 for pemphigus vulgaris (PV).
SN1011 is the first Bruton's tyrosine kinase (BTK) known for the treatment of PV in
China with huge unmet clinical needs. The IND approval would enable the company to conduct
comprehensive clinical development programs for the treatment of PV in China. This would
be the second targeted indication of SN1011, following the approval of systemic lupus
erythematous (SLE) indication in August 2020. The first healthy subject had been
successfully dosed in Phase I clinical trial for SLE in Shanghai, China on 15 January
2021, and Phase I clinical trial is in good progress. (RC)

Back to Others

Remark: Real time quote last updated: 23/09/2024 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.